

Developing small-molecule drugs with modern mechanisms of action, specializing in oncology

This report is an English translation of part of the report issued on June 18, 2024.
For inquiries concerning the report, please contact info@stock-r.org

[190A Chordia Therapeutics Sector : Pharmaceutical]

Fiscal Year	Net sales (mn yen)	YoY (%)	Operating profit (mn yen)	YoY (%)	Ordinary profit (mn yen)	YoY (%)	Profit (mn yen)	YoY (%)	EPS (yen)	BPS (yen)	DPS (yen)
Aug. 2022	-	-	-1,844	-	-1,776	-	-1,779	-	-39.8	-72.4	0.0
Aug. 2023	2,500	-	212	-	225	-	223	-	4.0	79.3	0.0
Aug. 2024 f	-	-	-2,273	-	-2,278	-	-2,280	-	-40.4	-	0.0

Note: Non-consolidated basis. Figures for the fiscal year ending August 2024 is the company's forecasts.
It conducted 1:200 stock split on June 2, 2023. Per share indices are adjusted retroactively.

Developing Small-Molecule Drugs with Modern Mechanisms of Action, Specializing in Oncology

Chordia Therapeutics is a bio-venture company established by Takeda Pharmaceuticals researchers through Takeda Pharmaceuticals' Entrepreneurship Venture Program.

The company is engaged in the research and development of first-in-class small-molecule drugs with modern mechanisms of action specifically for cancer treatment. First-in-class drugs are defined as innovative drugs that are highly novel, useful and significantly alter conventional treatment systems.

Promoting Research and Development of Anti-Cancer Drugs Targeting RNA Deregulation Stress

The company's R&D targets RNA deregulation stress, a cancer hallmark identified in recent years. RNA deregulation stress is a condition that occurs when the RNA production process, responsible for protein production in the cell, is disrupted and aberrant RNA accumulates, applying load on the cell. Compared with normal cells, cancer cells are overloaded. The anti-cancer effect is achieved through a mechanism of action that selectively causes cancer cells to die by further production and accumulation of aberrant RNA.

Chordia Therapeutics is a research and development leader in anti-cancer drugs targeting RNA deregulation stress, which are not yet commercially available as pharmaceutical products.

Business Model and Earnings Structure

Chordia Therapeutics focuses on research work such as drug exploration, preclinical and clinical research, particularly in the discovery, evaluation, optimization and clinical testing of candidate compounds. The company outsources basic research, manufacturing of drug substances and formulations, distribution and sales to external partners.

Financial Statements

Statement of income	Fiscal Year	Aug. 2022		Aug. 2023		Six months to Feb.2024	
		(mn yen)	(%)	(mn yen)	(%)	(mn yen)	(%)
Operating revenue		-	-	2,500	100.0	-	-
Operating expense		1,844	-	2,287	91.0	809	-
Operating profit		-1,844	-	212	8.5	-809	-
Non-operating income		94	-	25	-	11	-
Non-operating expenses		27	-	12	-	3	-
Ordinary profit		-1,776	-	225	9.0	-801	-
Profit before income taxes		-1,776	-	225	9.0	-801	-
Net profit		-1,779	-	223	8.9	-802	-

Balance sheet	Fiscal Year	Aug. 2022		Aug. 2023		Feb.2024	
		(mn yen)	(%)	(mn yen)	(%)	(mn yen)	(%)
Current assets		4,482	99.6	4,891	99.6	3,885	99.6
Cash and deposits		4,254	94.6	4,799	97.8	3,746	96.0
Accounts receivable-trade		-	-	-	-	-	-
Inventories		-	-	-	-	-	-
Non-current assets		16	0.4	17	0.3	16	0.4
Property, plant and equipment		8	0.2	4	0.1	3	0.1
Intangible assets		4	0.1	2	0.0	1	0.0
Investments and other assets		4	0.1	10	0.2	11	0.3
Total assets		4,498	100.0	4,909	100.0	3,902	100.0
Current liabilities		221	4.9	408	8.3	204	5.2
Accounts payable - trade		-	-	-	-	-	-
Non-current liabilities		-	-	-	-	-	-
Net assets		4,277	95.1	4,500	91.7	3,698	94.8
Owners' equity		4,251	94.5	4,474	91.1	3,672	94.1

Statement of cash flows	Fiscal Year	Aug. 2022		Aug. 2023		Six months to Feb.2024	
		(mn yen)	(mn yen)	(mn yen)	(mn yen)		
Cash flows from operating activities		-1,704	543	-1,052			
Depreciation		3	6	2			
Cash flows from investing activities		-14	0	0			
Cash flows from financing activities		3,975	-	-			
Dividends paid		-	-	-			
Net increase in cash and cash equivalents		2,256	544	-1,052			
Cash and cash equivalents		4,254	4,799	3,746			

Note: Non-consolidated

Source: Prepared by Stock Research Center based on the notifiable prospectus.

About Stock Research Center

Stock Research Center is engaged in the preparation of analyst reports, mainly on companies that are not sufficiently covered by analysts, based on a neutral perspective, and broadly disclose the reports to the public with an aim to revitalize the stock market.

Note: Reports prepared by Stock Research Center are created in reference to the Ministry of Economy, Trade and Industry's Guidance for Integrated Corporate Disclosure and Company-Investor Dialogues for Collaborative Value Creation.



■ Supporting Members

Tokyo Stock Exchange, Inc.

Nomura Securities Co., Ltd.

KPMG AZSA LLC

Deloitte Touche Tohmatsu LLC

PricewaterhouseCoopers Japan LLC

GYOSEI & CO.

PRONEXUS INC.

The Securities Analysts Association of Japan

SMBC Nikko Securities Inc.

Mizuho Securities Co., Ltd.

ICMG Co., Ltd.

SBI SECURITIES Co., Ltd.

Ichiyoshi Securities Co., Ltd.

Avantia G.P.

Japan Securities Dealers Association

Daiwa Securities Co. Ltd.

Ernst & Young ShinNihon LLC

Grant Thornton Taiyo LLC

BDO Sanyu

A&A Partners

TAKARA PRINTING CO., LTD.

■ Endorsement

Nagoya Stock Exchange, Inc.

Japan Venture Capital Association

Sapporo Securities Exchange

Japan Investor Relations Association

Certification by Analysts

Analysts indicated in the reports certify that the content indicated in the report precisely reflects the personal opinions of the analysts on all securities and issuer companies discussed in the report. In addition, it is ensured that the opinions directly or indirectly indicated in the report will have no influence on the analyst's compensation in the past, present, and future upon writing the report.

Disclaimer

- The report is prepared by stock analysts affiliated with the Stock Research Center for the purpose of disclosure to a wide range of investors as reference information and not to recommend or solicit to buy or to sell any particular securities or financial instrument.
- The content and indication of the report is based on disclosed information available publicly and is prepared by adding necessary supplementary information gained through interviews by analysts. The writer of the report is, without exception, prohibited to use insider information, or to acquire such information. The information included in the report is believed to be precise and reliable, but its preciseness is not verified objectively. In addition, the report is not intended to comprehensively include all information required by investors.
- The information included in the report may become outdated due to changes in the financial market, economic environment, etc. There are risks that the prices of stocks featured directly or indirectly in the report will fall below the par value due to fluctuations in stock prices, changes in management/financial conditions of the issuers, fluctuations in exchange rates or interest rates, etc. Past performance does not imply or guarantee future performance.
- The opinions indicated in the report are subject to change without notice and the Stock Research Center has no obligation to update the information or opinions included in the report.
- The Stock Research Center does not bear any responsibility for any results, including direct losses, indirect losses, losses of profit and damages, suffered by investors due to using the report or relying on the report. Final investment decisions shall be made by investors themselves and the sole responsibility concerning the investment lies with the investors that viewed the report.
- The copyright of the report belongs to the Stock Research Center and it may not be copied, reproduced, quoted, etc. in any form without prior consent.